United Therapeutics Corp. (UTHR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about United Therapeutics Corp. (UTHR)
Go deeper and ask any question about UTHR
Company Performance
Current Price
as of Sep 13, 2024$339.12
P/E Ratio
15.58
Market Cap
$15.09B
Description
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Metrics
Overview
- HQSilver Spring, MD
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerUTHR
- Price$339.12-0.58%
Trading Information
- Market Cap$15.09B
- Float98.25%
- Average Daily Volume (1m)447,845
- Average Daily Volume (3m)516,175
- EPS$23.11
Company
- Revenue$2.62B
- Rev Growth (1yr)19.85%
- Net Income$278.10M
- Gross Margin89.12%
- EBITDA Margin47.36%
- EBITDA$338.60M
- EV$12.66B
- EV/Revenue4.84
- P/E15.58
- P/S6.16
Documents
SEC Filings
Earnings Calls
Factset Street Account
StreetAccount Metrics Recap - United Therapeutics Q3 Earnings ($222.86, 0.00) (2023-11-01T10:05:11Z)
Wikipedia